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http://dx.doi.org/10.1016/j.ccr.2014.07.006SUMMARYPonatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single
mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1T315I
mutant. However, emergence of compoundmutations in aBCR-ABL1 allele may confer ponatinib resistance.
We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer vary-
ing resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib, and bosutinib. T315I-inclusive com-
pound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was428 Cancer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemiapredictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-
based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that
BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment
selection to optimize clinical outcome.INTRODUCTION
Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 (Druker
et al., 2006) have dramatically improved the prognosis of chronic
myeloid leukemia (CML) and, to a lesser extent, Philadelphia
chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
However, TKI resistance occurs in 20%–30% of CML patients
(O’Hare et al., 2012) and is commonly attributable to point muta-
tions in the BCR-ABL1 kinase domain. The TKIs approved for
first-line therapy, imatinib (Apperley, 2007; Azam et al., 2003;
Bradeen et al., 2006), nilotinib (Weisberg et al., 2005), and dasati-
nib (Shah et al., 2004), and the second-line therapy, bosutinib
(Cortes et al., 2011; Redaelli et al., 2009), demonstrate overlap-
ping resistance profiles, with the BCR-ABL1T315I mutant a shared
vulnerability (O’Hare et al., 2012). Additionally, some patients fail
therapy despite inhibition of BCR-ABL1, implicating activation of
alternative, BCR-ABL1 kinase-independent resistance mecha-
nisms (Dai et al., 2004;Donato et al., 2003;Hochhauset al., 2002).
Ponatinib (O’Hare et al., 2009) is a high-affinity, pan-BCR-
ABL1 TKI with the unique property of inhibiting BCR-ABL1T315I.
Anti-leukemic activity has been observed in clinical trials of
ponatinib, including patients with BCR-ABL1T315I, although re-
sponses in patients with blastic phase CML (CML-BP) or Ph+
ALL are typically transient (Cortes et al., 2012, 2013). After a
hold due to safety concerns pertaining to vascular occlusion
events, regulatory approval in the United States was reinstated
for patients with refractory Ph+ leukemia harboring BCR-
ABL1T315I or for whom no other TKI is indicated (Senior, 2014).
A risk of sequential TKI treatment is the selection of BCR-ABL1
compound mutants, defined as a BCR-ABL1 allele harboring
two or more mutations, that have the potential to confer resis-
tance to multiple TKIs (Shah et al., 2007). Vulnerability of
ponatinib to certain two-component compound mutations was
demonstrated in preclinical studies (O’Hare et al., 2009), sug-
gesting theymay emerge as a clinical problem in patients treated
with ponatinib. Importantly, ultra-deep sequencing of serial sam-
ples fromPh+ leukemia patients who had received sequential TKI
treatment showed that the majority (76%) of BCR-ABL1 com-
pound mutations were two-component mutations, as compared
to 21% triple and 3% quadruple mutations (Soverini et al., 2013).
Progress in the development of a next generation sequencingSignificance
In patients with Ph+ leukemia, control of TKI resistance due to B
clinically available TKIs to target BCR-ABL1 compound muta
study reveal that BCR-ABL1 compound mutations impart vario
itive sequencing screens to distinguish these from polyclonal
patients harboring compound mutations will improve disease
other malignancies in which compound mutations are a predic
and non-small cell lung cancer.
Caapproach spanning the BCR-ABL1 kinase domain in a single
read was recently reported (Kastner et al., 2014).
The ability of available TKIs to address resistance due to clin-
ically reported BCR-ABL1 compound mutants has yet to be
investigated. In this study, we inventoried clinically reported
BCR-ABL1 compound mutations and established in vitro TKI
sensitivity profiles of BCR-ABL1 compound mutants against a
panel of clinically available TKIs.
RESULTS
Key BCR-ABL1 Kinase Domain Positions Are Frequently
Represented in Clinically Reported Compound Mutants
Over 100 BCR-ABL1 kinase domain point mutations have been
linked with clinical imatinib resistance (Apperley, 2007), and
resistance profiles for newer BCR-ABL1 TKIs are mainly
comprised of subsets of these mutations. In the current study,
all uses of the term ‘‘compound mutation’’ refer to two-compo-
nent compoundmutations unless otherwise stated. Thorough in-
ventory of clinical BCR-ABL1 compound mutations associated
with TKI resistance reported in the published literature identified
a limited list of 12 kinase domain positions (Figure 1A)
comprising the majority of compound mutations, which we refer
to as key positions. All clinically reported compound mutations
(100%) in Figure 1 include a key position, and the majority
(65%) involve two (Figures 1B and 1C). Each position has been
implicated in resistance to one or more TKIs: imatinib (Bradeen
et al., 2006; Gorre et al., 2001), nilotinib (Bradeen et al., 2006;
Ray et al., 2007; Weisberg et al., 2005), dasatinib (Bradeen
et al., 2006; Burgess et al., 2005; Shah et al., 2004), bosutinib
(Redaelli et al., 2009), ponatinib (O’Hare et al., 2009), and rebas-
tinib (Chan et al., 2011; Eide et al., 2011). The key residues in
native BCR-ABL1 are: M244, G250, Q252, Y253, E255, V299,
F311, T315, F317, M351, F359, and H396 (Figure 1A). Clinical
examples of T315I paired with all key positions except 299 and
317 have been reported (Figure 1B and Figure S1A available
online). Among 66 possible pairings of the 12 key positions, 30
(45%) have been reported to date (Figures 1B, 1C, and S1B).
Further variations at the specific substitution level also occur,
for example T315I/F359C and T315I/F359V (Figure 1B) or
E255K/F317L and E255V/F317I (Figure 1C).CR-ABL1 single mutants is now achievable, but the ability of
nts has yet to be thoroughly investigated. Results from this
us levels of TKI resistance, underscoring the need for defin-
mutations and suggesting that optimal therapy selection for
control in Ph+ leukemia. These findings may also apply to
ted route of therapy escape, such as acute myeloid leukemia
ncer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc. 429
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Figure 1. Clinically Reported BCR-ABL1 Compound Mutations Are Centered on 12 Key Positions
(A) Crystal structure of the ABL1 kinase domain in complex with imatinib (PDB entry 2HYY). The 12 key positions accounting for most clinical BCR-ABL1 TKI
resistance, including compound mutation-based resistance, are highlighted (orange; T315 is in red). The phosphate-binding (yellow) and activation loops (green)
are indicated.
(B and C) Key resistance positions (orange) in clinically reported T315I-inclusive (B) and non-T315I BCR-ABL1 compound mutants (C). Substitutions at non-key
positions are in gray. 1, Shah et al., 2007; 2, Khorashad et al., 2008; 3, Stagno et al., 2008; 4, Kim et al., 2010; 5, Kim, D.W. et al., Blood 2010 abstract 3443;
6, Khorashad et al., 2013; 7, Smith, C.C., et al., Blood 2011, abstract 3752; 8, Soverini et al., 2013; 9, Cortes et al., 2013; 10, Hochhaus et al., 2013; *, the
current study.
See also Figure S1 and Table S1.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ LeukemiaRelevance for these key positions in TKI resistance is further
supported by baseline conventional sequencing traces of 439
patients entering the phase 2 Ponatinib Ph+ ALL and CML
Evaluation (PACE) trial (Cortes et al., 2013). Enrollment required:
(1) resistance to or unacceptable toxicity from nilotinib or dasa-
tinib, or (2) a documented baseline T315I mutation. Mutations
occurring in more than 1 patient were confined to 16 positions,
including 11/12 key positions (all except Q252). In total, 95.4%
(270/283) of the mutations observed in >1 patient among base-
line PACE specimens occurred at key positions. For PACE end430 Cancer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Incof treatment (EOT) specimens, 93.8% (15/16) of two-component
compound mutations inferred from conventional sequencing
involved two key positions (Table S1).
Clinically Available Tyrosine Kinase Inhibitors Exhibit
Differential Activity against BCR-ABL1 Compound
Mutants
Proliferation assays comparing six TKIs were performed with
Ba/F3 cells expressing native BCR-ABL1, BCR-ABL1 single mu-
tants at each of the 12 key positions, and clinically reported.
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Figure 2. Single and Compound BCR-ABL1 Mutants Exhibit Differential TKI Sensitivity in Ba/F3 Cells
(A and B) Cell proliferation IC50 values of TKIs against BCR-ABL1 single mutants (A), T315I-inclusive (B, left) and non-T315I (B, right) compound mutants. Mean
IC50 values are plotted. Blue lines denote average steady-state plasma concentration of each TKI in patients taking the standard daily dose: imatinib (400 mg;
3,377 nM) (Peng et al., 2004; Gozgit et al., Blood 2013, abstract 3992), nilotinib (400 mg twice daily; 2,754 nM) (Kantarjian et al., 2006; Gozgit et al., Blood 2013,
abstract 3992), dasatinib (100 mg; 27 nM) (Gozgit et al., Blood 2013, abstract 3992; Talpaz et al., 2006), ponatinib (15, 30, and 45 mg/day doses are represented;
35, 84, and 101 nM, respectively) (Cortes et al., 2012; Gozgit et al., Blood 2013, abstract 3992), rebastinib (150 mg twice daily; 350 nM) (Chan et al., 2011; Eide
et al., 2011), and bosutinib (500 mg; 287 nM) (Gozgit et al., Blood 2013, abstract 3992).
(C) Heat map of TKI IC50s for single and compound mutants. I315M (see Figure 6) and T315I/E453K (see Figure 5) are included for comparison. A color gradient
from green (sensitive) to yellow (moderately resistant) to red (highly resistant) denotes the IC50 sensitivity to each TKI: imatinib (green: <1,000 nM; yellow: 1,000–
4,000 nM; red: >4,000 nM); nilotinib (green: <200 nM; yellow: 200–1,000 nM; red: >1,000 nM); dasatinib (green: <25 nM; yellow: 25–150 nM; red: >150 nM);
ponatinib (green: <25 nM; yellow: 25–150 nM; red: >150 nM); rebastinib (green: < 100 nM; yellow: 100–1,000 nM; red: >1,000 nM); bosutinib (green: <150 nM;
yellow: 150–1,000 nM; red: >1,000 nM).
(D and E) BCR-ABL1 tyrosine phosphorylation (Y393) immunoblot analysis of T315I-inclusive (D) and non-T315I (E) compound mutants. NT, no treatment.
See also Table S2.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ LeukemiaBCR-ABL1 compound mutants (Khorashad et al., 2008; Kim
et al., 2010; Shah et al., 2007; Stagno et al., 2008). Except for
I315M (see below), each single mutant was effectively inhibited
by at least one TKI and exhibited a half-maximal inhibitory con-
centration (IC50) value below the average steady-state plasma
TKI concentration reported for patients receiving the standard
drug dose (Figure 2). The six TKIs displayed partially overlapping
resistance profiles for BCR-ABL1 single mutants, with T315I in-
hibited only by ponatinib and rebastinib.
T315I-inclusive compoundmutants were insensitive to all TKIs
except ponatinib and rebastinib, which exhibited only marginalCaefficacy in most cases (Figures 2B and 2C). The most resistant
mutant, E255V/T315I (IC50: 659.5 nM), exhibited 11.9- and
22.7-fold higher ponatinib resistance than E255V (IC50:
55.6 nM) or T315I (IC50: 29.1 nM; Table S2), respectively. The
IC50 for E255V/T315I is >6.5-fold the average steady-state
plasma concentration (101 nM) for patients receiving ponatinib
at the PACE starting dose (45 mg/day; Cortes et al., 2012). The
Q252H/T315I, T315I/M351T, T315I/F359V, and T315I/H396R
mutants exhibited marginal ponatinib sensitivity (IC50: 84.8-
114.3 nM) and high-level rebastinib resistance (IC50: 464.6-
955.3 nM).M244V/T315I was the only T315I-inclusive compoundncer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc. 431
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemiamutant in the panel predicted to be sensitive to ponatinib and
rebastinib at clinically achievable levels (Figure 2; Table S2).
In vitro sensitivity of T315I-inclusive mutants was correlated to
the degree of BCR-ABL1 Y393 phosphorylation (a marker of
kinase activity) by immunoblot analysis (Figure 2D).
All non-T315I compound mutants analyzed were inhibited by
one or more TKIs (Figure 2B). For some compound mutants
(e.g., Y253H/F317L), several TKI options exist. For others, a
single TKI stands out as the leading choice, most notably dasa-
tinib for Y253H/E255V (Figures 2B and 2C; Table S2). Superiority
of dasatinib compared to ponatinib (which demonstrate similar
low nanomolar IC50s against native BCR-ABL1) against this
particular compound mutant was further confirmed by immuno-
blot analysis, which revealed substantial residual pBCR-ABL1
signal for ponatinib compared to dasatinib at 100 nM (Figure 2E).
All other non-T315I compound mutants were effectively sup-
pressed by ponatinib at concentrations below the steady-state
plasma concentrations of 45 mg/day (101 nM) and 30 mg/day
(84 nM) doses. In addition to Y253H/E255V, only E255V/V299L
(IC50: 42.8 nM) and F317L/F359V (IC50: 53.2 nM) were not
inhibited at the steady-state plasma concentration for the
15 mg/day (35 nM) dose. It is conceivable that ponatinib doses
lower than 15mg/day may not be able to prevent the emergence
of additional compound mutants. In summary, non-T315I BCR-
ABL1 compound mutants exhibited a spectrum of TKI sensitiv-
ities, suggesting in vitro resistance profiles may serve as a guide
for clinical TKI selection.
Computational Modeling of Y253H/E255V Rationalizes
Differential Tyrosine Kinase Inhibitor Sensitivity
Ponatinib binds to the ABL1 kinase domain in the DFG-out
mode, recognizing an inactive conformation of the kinase
(O’Hare et al., 2009; Zhou et al., 2011). The binding site of pona-
tinib is centered on the adenine pocket of the enzyme and ex-
tends from the phosphate-binding loop (P loop) to the C-helix
region. By contrast, dasatinib binding is accompanied by fewer
conformational constraints and is less dependent on direct P
loop and C-helix interactions (Tokarski et al., 2006). Since pona-
tinib compared favorably with dasatinib against all non-T315I
compound mutants except Y253H/E255V, we investigated
structural features that account for the striking difference in
the case of this compound mutant (ponatinib IC50: 203.5 nM;
dasatinib IC50: 18.1 nM; Table S2). Molecular dynamics simula-
tions were carried out for a protracted interval (100 ns), and
docking simulations were performed using the GlideXP method
(Suite 2012: GlideXP, version 5.8, Schro¨dinger, New York, NY,
2012) on a collection of 50 Y253H/E255V conformations ex-
tracted at regular intervals. Introduction of Y253H and E255V
noticeably shifted the P loop, impinging on the ponatinib binding
site (Figure 3A). Loss of Y253-F382 aromatic p-p stacking also
pushed F382 into the ponatinib site (Figures 3B and S2), and
disruption of the critical K271-E286 salt bridge in the inactive
conformation repositioned residues L248, K271, E286, and
R362 (Figures 3B and S2). In contrast, modeling predicted that
dasatinib forms a new hydrogen bond with H253 in the
Y253H/E255V mutant and that realignments relative to native
BCR-ABL1 do not obstruct dasatinib binding (Figures 3C and
3D). Thus, in vitro experimental results and computational
modeling (Figures 2B, 2C, and 3E) identify dasatinib as the432 Cancer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inconly TKI that retains potency against Y253H/E255V at clinically
relevant levels.
Conventional and Clonal Sequencing Establish
Correlations betweenBaselineMutations andResponse
to Ponatinib
To understand the role of compound mutations for ponatinib
response and resistance, we received and analyzed 100 speci-
mens from 64 patients treated on the PACE trial (n = 50) or pona-
tinib expanded access program (n = 14), using both conventional
Sanger sequencing and clonal sequencing of an average of 85
individual BCR-ABL1 kinase domain amplicons per specimen.
Clinical specimens originated from patients enrolled at centers
participating in the PACE trial that elected to participate in an
investigator-initiated companion protocol. The cloning and
sequencing approach is an order of magnitude more sensitive
and differentiates compound from polyclonal mutations, allow-
ing greater insight into the role of compound mutations in TKI
resistance. Pre-ponatinib baseline samples were evaluated for
all patients; for 30 patients, longitudinal and/or EOT specimens
were also analyzed. Patients were grouped according to base-
line mutation status assessed by conventional sequencing: (1)
T315I, (2) mutation other than T315I, or (3) no mutation. There
were 31 patients that were in the chronic phase (CML-CP), 14
in the accelerated phase (CML-AP), and 19 in CML-BP or with
Ph+ ALL. The cohort was heavily pretreated: 31 patients (48%)
had been exposed to two TKIs and 29 (45%) to three or more
TKIs. Prior TKI exposure, baseline mutation status, response,
and outcome are summarized in Table 1.
Patients with a T315I Baseline Mutation
T315I was detected at baseline in 22/64 patients (34.4%),
including eight CML-CP, six CML-AP, five CML-BP, and three
Ph+ ALL patients (Table S3). There were three patients that car-
ried a second baseline mutation: K285E (#2), F317L (#10), or
H396R (#18).
Patients with a Mutation Other Than T315I at Baseline
Non-T315I baseline mutations were found in 17/64 patients
(26.6%), representing all non-T315I key positions except 244
and 311: nine CML-CP, three CML-AP, two CML-BP, and three
Ph+ ALL (Table S4). Most baseline samples (11/17; 64.7%)
harbored a mutation at a single position; six had mutations at
two positions: F317L; E450G (#23), F317L; E459K (#27),
E255V; F317L (#32), F317I; F359V (#34), Y253H; E255V (#35),
and G250E; F317L (#39).
Patients with No Baseline BCR-ABL1 Mutation
Lack of a baseline mutation was observed in 25/64 patients
(39.1%): 14 CML-CP, five CML-AP, four CML-BP, and two Ph+
ALL (Table S5). No patient lacking a baseline mutation who dis-
continued ponatinib harbored a compound mutation at EOT,
suggesting a degree of BCR-ABL1-independent resistance prior
to initiating ponatinib therapy as well as at ponatinib failure. In
the following, we evaluated outcomes on ponatinib therapy for
patients carrying a baseline T315I or non-T315I mutation.
T315I-Inclusive Compound Mutations Are Associated
with Ponatinib Failure
Our in vitro profiling of T315-inclusive compound mutants
predicts that most pairings with a second key position will
confer moderate- to high-level ponatinib resistance (Figure 2)..
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NY, 2012).
(E) Fold-change in cellular IC50 for BCR-ABL1
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See also Figure S2.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ LeukemiaAccordingly, we observed three patients who discontinued po-
natinib due to marked expansion of a T315I-inclusive compound
mutation. Patient #38 (Tables S4 and S6) presentedwith Ph+ ALL
previously refractory to imatinib and dasatinib. Cloning and
sequencing (n = 84 clones) confirmed a predominant E255V mu-
tation (85% of clones), including as an E255V/T315I compound
mutation (17% of clones). Transient response to ponatinib was
followed by rapid hematologic relapse and a detection of a
dominant E255V/T315I compoundmutation (69% of clones; Fig-
ure 4A). Molecular dynamics simulations traced the reduced
affinity of ponatinib toward E255V/T315I compared to T315I
alone to reorientation of the P loop and C-helix necessary to
accommodate the hydrophobic V255 side chain (Figure 4B).
These adjustments force the L248 and I315 side chains into
the ponatinib site, repositioning residues M290, F359, and
D381 and reducing the distance between F382 and I315, which
narrows the channel into which ponatinib normally binds (Figures
4C and S2).CaA second patient (#36, CML-BP; Table S4) had a baseline
F359C mutation and later experienced disease progression
attributable to a T315I/F359C mutation that was not detectable
in the baseline clonal sequencing profile (Figures 5A and 5B;
Table S7). This compound mutant was recovered in Ba/F3
BCR-ABLT315I cell-based resistance screens for ponatinib
(O’Hare et al., 2009) and rebastinib (Eide et al., 2011), in line
with our in vitro profiles implicating mutant pairing of these two
positions in moderate and high-level resistance to these TKIs,
respectively.
Last, a CML-AP patient (#12; Tables S3 and S7) with a baseline
T315I mutation treated with ponatinib (45 mg/day) experienced
disease progression with a T315I/E453K mutation (90% of
clones) not detected at baseline by conventional sequencing
or cloning and sequencing (Figure 5C). The E453K mutation
has been reported in imatinib resistance (Soverini et al., 2013),
but not compound mutation-based resistance. Ba/F3 BCR-
ABL1T315I/E453K cells showed a substantially higher level ofncer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc. 433
Table 1. Patient Characteristics: Prior TKI Exposure, Baseline Mutation Status, Response, and Outcome
CML-CP CML-AP CML-BP/Ph+ ALL
Total
T315I
Mutation
Mutation
Other than
T315I
No
Mutation Total
T315I
Mutation
Mutation
Other than
T315I
No
Mutation Total
T315I
Mutation
Mutation
Other than
T315I
No
Mutation
n = 31 n = 8 n = 9 n = 14 n = 14 n = 6 n = 3 n = 5 n = 19 n = 8 n = 5 n = 6
Prior TKI exposure, n (%)
1 TKI 3 (10) 2 (25) 0 (0) 1 (7) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 1 (13) 0 (0) 0 (0)
2 TKIs 12 (39) 5 (63) 5 (56) 2 (14) 7 (50) 3 (50) 1 (33) 3 (60) 12 (63) 6 (75) 4 (80) 2 (33)
R3 TKIs 16 (52) 1 (13) 4 (44) 11 (79) 7 (50) 3 (50) 2 (67) 2 (40) 6 (32) 1 (13) 1 (20) 4 (67)
Best hematologic response on ponatinib, n (%)a
<MaHR 1 (3) 0 (0) 0 (0) 1 (7) 0 (0) 0 (0) 0 (0) 0 (0) 3 (16) 0 (0) 1 (20) 2 (33)
MaHR 1 (3) 1 (13) 0 (0) 0 (0) 1 (7) 0 (0) 1 (33) 0 (0) 5 (26) 2 (25) 1 (20) 2 (33)
CHR 29 (94) 7 (89) 9 (100) 13 (93) 13 (93) 6 (100) 2 (67) 5 (100) 11 (58) 6 (75) 3 (60) 2 (33)
Best cytogenetic response on ponatinib, n (%)b
<pCyR 12 (39) 2 (25) 5 (56) 5 (36) 6 (43) 2 (33) 1 (33) 3 (60) 8 (42) 1 (13) 2 (40) 5 (83)
pCyR 4 (13) 1 (13) 0 (0) 3 (21) 3 (21) 1 (17) 1 (33) 1 (20) 5 (26) 4 (50) 1 (20) 0 (0)
CCyR 15 (48) 5 (63) 4 (44) 6 (43) 5 (36) 3 (50) 1 (33) 1 (20) 6 (32) 3 (38) 2 (40) 1 (17)
Best molecular response on ponatinib, n (%)c
<MMR 20 (65) 4 (50) 6 (67) 10 (71) 10 (71) 4 (67) 2 (67) 4 (80) 18 (95) 8 (100) 4 (80) 6 (100)
RMMR 11 (35) 4 (50) 3 (33) 4 (29) 4 (29) 2 (33) 1 (33) 1 (2) 1 (5) 0 (0) 1 (20) 0 (0)
Treatment follow-up
Median duration of ponatinib treatment,
months (range)
13.6 (2.8–
34.2)
11.1 (2.8–
32.4)
15.1 (6.1–
30.4)
13.6 (3.3–
34.2)
17.1 (3.6–
30.8)
19.3 (5.5–
30.8)
17.6 16.6–
27.6)
13.8 (3.6–
29.7)
3.7 (0.4–
19.5)
3.6 (0.5–
16.3)
5.6 (1.3–
19.5)
2.9 (2.0–
16.3)
Remain on ponatinib therapy, n (%) 14 (45) 5 (63) 4 (44) 5 (36) 6 (43) 2 (33) 2 (67) 2 (40) 0 (0) 0 (0) 0 (0) 0 (0)
Discontinued, n (%) 17 (55) 3 (38) 5 (56) 9 (64) 8 (57) 4 (67) 1 (33) 3 (60) 19 (100) 8 (100) 5 (100) 6 (100)
Outcome follow-up, n (%)
Alive at last follow-up 28 (90) 6 (75) 8 (89) 14 (100) 8 (57) 3 (50) 2 (67) 3 (60) 7 (37) 3 (38) 1 (20) 3 (50)
Deceased at last follow-up 3 (10) 2 (25) 1 (11) 0 (0) 6 (43) 3 (50) 1 (33) 2 (40) 12 (63) 5 (63) 4 (80) 3 (50)
BCR-ABL1 cloning and sequencing, n (%)
Baseline samples analyzed 31 (100) 8 (100) 9 (100) 14 (100) 13 (93) 6 (100) 2 (67) 5 (100) 19 (100) 8 (100) 5 (100) 6 (100)
Longitudinal samples analyzed 7 (23) 2 (25) 4 (44) 1 (7) 4 (29) 1 (17) 2 (67) 1 (20) 3 (16) 1 (13) 1 (20) 1 (17)
End of treatment samples analyzed 4 (13) 0 (0) 1 (11) 3 (21) 5 (36) 3 (50) 0 (0) 2 (40) 9 (47) 4 (50) 2 (40) 3 (50)
Compound mutations emergent/persistent
in failure
0 (0) 0 (0) 0 (0) 0 (0) 1 (7) 1 (17) 0 (0) 0 (0) 6 (32) 3 (38) 3 (60) 0 (0)
See also Tables S3–S5.
aMaHR, Major hematologic response; CHR, complete hematologic response.
bpCyR, partial cytogenetic response; CCyR, complete cytogenetic response.
cMMR, major molecular response.
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Figure 4. BCR-ABL1E255V/T315I Exhibits Severely Compromised TKI Binding and Is Detected at Clinical Relapse on Ponatinib
(A) Summary ofBCR-ABL1 cloning and sequencing for patient #38 (Ph+ ALL) at baseline (upper) and EOT (lower) by cloning and sequencing individual amplicons.
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key positions, respectively. In this patient, a dominant, pan-TKI resistant E255V/T315I mutant was detected at the time of ponatinib failure.
(B) Molecular dynamics comparison of E255V/T315I (blue; V255 in red) and T315I mutants (orange; E255 in green).
(C) Structural realignments in E255V/T315I (cyan) compared to the T315I mutant (orange).
See also Figure S3 and Table S6.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemiaponatinib resistance (IC50: 93.4 nM) relative to those expressing
the T315I mutant (Figure 5D) and were insensitive to all other
TKIs tested except rebastinib (IC50: 322.9 nM) (Figures 2B and
2C). Both ponatinib and rebastinib were effective only at clini-
cally unachievable concentrations (Figure 2B). Among these
three examples, the T315I-inclusive EOT mutation was also
detectable at baseline in only one case (E255V/T315I), suggest-
ing the mutation was acquired on therapy or was below the
detection limit of cloning and sequencing in the other two cases.
There were two additional patients in our study (#17 and #18;
Tables S3 and S6) that had ponatinib-resistant EOT mutations
that already predominated at baseline (Y253H/T315I and
T315I/H396R, respectively; Figure S3). Altogether, these find-
ings suggest that T315I-inclusive compound mutations signifi-
cantly impair ponatinib binding and typically lead to clinical
resistance and relapse.
The I315M Mutation Emanates from T315I and Confers
High-Level Ponatinib Resistance
Nearly every instance of BCR-ABL1 kinase domain mutation-
based ponatinib failure was attributable to a compoundmutation
pairing two key positions. However, in the case of a Ph+ ALL
patient (#22; Figure 6A; Tables S3 and S8) with a baseline
T315I mutation who achieved a complete cytogenetic responseCa(CCyR) on ponatinib (45mg/day), but progressed after 7months,
longitudinal and EOT cloning and sequencing revealed a change
of I315 tomethionine (I315M) through a single nucleotide change
(ATT to ATG). We previously recovered the ponatinib-resistant
I315M mutant in Ba/F3 BCR-ABL1T315I cell-based resistance
screens (Eide et al., 2011; O’Hare et al., 2009), and in vitro
profiling of Ba/F3 BCR-ABL1I315M cells confirmed pan-TKI resis-
tance. The level of ponatinib resistance conferred by the I315M
mutation (IC50: 577.5 nM; Figure 6B) exceeded all tested single
and compound mutants except E255V/T315I (IC50: 659.5 nM).
Molecular dynamics simulations demonstrated direct encroach-
ment of the methionine residue on the ponatinib site (Figures 6C
and 6D) and that adjustments at positions 269, 290, 317, 359,
and 381 also disfavor ponatinib binding (Figures 6D, S2) and
disrupt the hydrophobic spine architecture (Azam et al., 2008).
These findings illustrate that I315M as a single point mutation
can lead to ponatinib treatment failure.
Non-T315I Compound Mutations Impart Differential
Levels of Tyrosine Kinase Inhibitor Resistance
In vitro evaluation of non-T315I compound mutants showed
varying levels of TKI sensitivity across the panel, with 7/8
mutants demonstrating sensitivity to ponatinib (Figure 2C).
Among patients for whom EOT samples were available, onlyncer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc. 435
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Figure 5. Clinical Emergence of T315I-Inclusive Compound Mutants Can Lead to Relapse
(A) Summary of BCR-ABL1 cloning and sequencing of individual clones for patient #36 (CML-BP) at baseline (upper) and EOT (lower). Conventional sequencing
results and prior TKIs are shown. Bar graphs are as in Figure 4.
(B) Fold-change in ponatinib Ba/F3 cellular IC50 values for BCR-ABL1
F359V and BCR-ABL1T315I/F359V compared to native BCR-ABL1.
(C) Summary of BCR-ABL1 cloning and sequencing for patient #12 (CML-AP). Samples were analyzed as in (A) at baseline (upper), while on ponatinib (middle),
and at EOT (lower).
(D) Fold-change in ponatinib Ba/F3 cellular IC50 values for BCR-ABL1
T315I and BCR-ABL1T315I/E453K compared to native BCR-ABL1. All error bars
represent ± SEM.
See also Table S7.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemiaone demonstrated clear evidence of a non-T315I compound
mutation at failure (#37, Ph+ ALL; Figure 7A; Tables S4 and
S9). Following treatment with imatinib and dasatinib, this patient
exhibited a baseline F317I mutation. The patient experienced
disease progression and discontinued ponatinib (45 mg/day),
with EOT sequencing revealing an E255V/F317I mutation
(100% of clones; Figure 7A).
In contrast, three patients with non-T315I compound muta-
tions at baseline achieved durable responses on ponatinib.
Patient #34 (Figure 7B; Tables S4 and S9) presented with
CML-AP and was treated with imatinib and dasatinib prior to436 Cancer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Incstarting ponatinib. There were two mutations (F317I and
F359V) identified in the baseline sample that were confirmed
as a predominant F317I/F359V compound mutation by cloning
and sequencing (Figure 7B). The patient achieved rapid com-
plete hematologic response (CHR) and a major molecular
response (MMR) within 7 months on ponatinib, at which time
the majority (87%) of sequenced clones remained F317I/
F359V. At last follow-up of 16 months, the patient continued to
maintain MMR.
There were two additional patients (#23 and #27; Tables S4,
S9) with non-T315I compound mutations predominant at.
T315I
I315MM315
I315
M290
I293
F359
D381
A269
F317
Ponatinib
sample 11-099
sample 12-341A
Pre-ponatinib:
Longitudinal:
Key Mutation Key + Additional
Key
Mutation:
Key
Mutation:
sample 12-341C
sample 11-296
Longitudinal:
EOT:
Key
Mutation:
Key
Mutation:
E255K/
T315I
E255K/
I315M
E255V/
T315I
E255V/
I315M
T315I I315M
0
20
40
60
80
100
%
of
se
qu
en
ce
d
cl
on
es
(n
=9
8)
None /I513TK552E
F317S
0
20
40
60
80
100
%
of
se
qu
en
ce
d
cl
on
es
(n
=1
00
)
E255K/
T315I
E255K/
I315M
E255V/
T315I
E255V/
I315M
T315I I315MNone E255K T315I/
F317S
0
20
40
60
80
100
%
of
se
qu
en
ce
d
cl
on
es
(n
=8
3)
E255K/
T315I
E255K/
I315M
E255V/
T315I
E255V/
I315M
T315I I315MNone E255K T315I/
F317S
0
20
40
60
80
100
%
of
se
qu
en
ce
d
cl
on
es
(n
=9
7)
E255K/
T315I
E255K/
I315M
E255V/
T315I
E255V/
I315M
T315I I315MNone E255K T315I/
F317S
Prior TKIs: I
Patient 22
Apr 2011
Baseline conventional seq:
T315I (100%)
Pre-ponatinib:
Ph ALL+
Jun 2011
Longitudinal conventional seq:
T315I (100%)
Nov 2011
Longitudinal conventional seq:
T315I; I315M
(30%; 70%)
Nov 2011
EOT conventional seq:
T315I; I315M
(25%; 75%)
BA
D
EOT due to 
progression
Ponatinib
C-helix
P-loop
T315I
I315M
M315
T3
15
I
I31
5M
0
50
100
150
200
Po
na
tin
ib
IC
Fo
ld
/N
at
ive
50
C
Relapse and 
progression
Responding
Figure 6. Acquired I315M Point Mutation-Based Ponatinib Failure in a Patient Harboring T315I at Onset of Therapy
(A) Summary of BCR-ABL1 cloning and sequencing for patient #22 (Ph+ ALL) at baseline (upper), longitudinally on ponatinib therapy (middle), and at EOT (lower)
by cloning and sequencing individual clones. Conventional sequencing results and prior TKIs are shown. Bar graphs are as in Figure 4.
(B) Fold-change in ponatinib Ba/F3 cellular IC50 values for BCR-ABL1
I315M and BCR-ABL1T315I compared to native BCR-ABL1. Error bars represent ± SEM.
(C) Ponatinib (in wireframe) in complex with ABL1T315I (orange); ABL1I315M (blue) is superimposed. Structural alignment of the T315I and I315M mutants was
performed as in Figure 3.
(D) M315 penetrates deeply into the ponatinib site, and structural adjustments at positions 269, 290, 293, 317, 359, and 381 also disfavor ponatinib binding.
See also Figure S4 and Table S8.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemiabaseline that showed marked reduction in the abundance of
the compound mutant clones on ponatinib therapy. After failing
four successive TKIs, patient #23 exhibited an F317L/E450G
baseline compound mutation (83% of clones; Figure 7C). The
patient achieved a CHR and stable disease on ponatinib for
over 2 years, discontinuing for undisclosed reasons. EOT
sequencing showed no F317L/E450G (Figure 7C), suggesting
this mutant is resistant to previous TKIs, but sensitive to
ponatinib. Similarly, CML-CP patient #27 (Tables S4 and S9)
exhibited an F317L/E459K baseline mutation (98% of clones;
Figure 7D) following failure of imatinib and dasatinib. After a
year on ponatinib and achievement of CHR, but neither CCyR
nor MMR, F317L/E459K was reduced to a minor component
(6% of clones), suggesting sensitivity to ponatinib. Compound
mutants pairing E459K with M244V, G250E, V299L (Kim et al.,
2009), and T315I have been reported (Figures 1B and 1C);Cathe current study reports F317L/E459K as a confirmed clinical
compound mutation. In summary, T315I-inclusive compound
mutations almost uniformly confer high-level resistance to all
clinically available TKIs including ponatinib, while a fraction of
non-T315I compound mutants remain sensitive to one or
more TKIs.
DISCUSSION
Drug-resistant compound mutations within the BCR-ABL1 ki-
nase domain are an emerging clinical problem for patients
receiving sequential TKI therapy. As we predicted for ponatinib
and rebastinib, some of these mutations confer resistance that
is several-fold higher than that of either contributing mutation
in isolation (Eide et al., 2011; O’Hare et al., 2009). We in-
vestigated the role of BCR-ABL1 compound mutations in TKIncer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc. 437
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Figure 7. Certain Non-T315I Compound Mutants Lead to Clinical Relapse, while Others Are Susceptible to Ponatinib
(A) Summary ofBCR-ABL1 cloning and sequencing for patient #37 (Ph+ ALL) at baseline (upper) and EOT (lower) by cloning and sequencing individual amplicons.
Conventional sequencing results and prior TKIs are shown. Bar graphs are as in Figure 4.
(B) Summary of BCR-ABL1 cloning and sequencing for patient #34 (CML-AP) at baseline (upper) and while responding to ponatinib (lower).
(C) Summary of BCR-ABL1 cloning and sequencing for patient #23 (CML-CP) at baseline (upper) and EOT (lower).
(D) Summary of BCR-ABL1 cloning and sequencing for patient #27 (CML-CP) at baseline (upper) and while responding to ponatinib (lower).
See also Table S9.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemia
438 Cancer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc.
Cancer Cell
Compound Mutants Cause TKI Failure in Ph+ Leukemiaresistance, focusing on ponatinib due to its unique effectiveness
against the T315I single mutant and clinical availability.
In the United States, ponatinib is approved for patients with re-
fractory CML or Ph+ ALL harboring a T315I mutation or for whom
no other TKI is indicated, based on results of the PACE trial
demonstrating significant activity at a median follow-up of
15 months (Cortes et al., 2013). Despite the impressive efficacy
of ponatinib, our findings indicate that compound mutations are
an important route of therapy escape, and it is conceivable that
dose reduction from 45 mg to 30 mg/day, as recommended for
patients with a good response to ponatinib, may increase the
emergence of drug-resistant compound mutants.
Our in vitro studies predict that a 30 mg/day dose would main-
tain efficacy against 7/8 non-T315I compound mutants tested in
our panel. At a daily dose of 15 mg, ponatinib is predicted to pre-
empt outgrowth of 5/8 non-T315I compound mutants in our
panel, with the Y253H/E255V, E255V/V299L, and F317L/F359V
mutants remaining potentially problematic. In contrast, thera-
peutic utility is less promising with respect to T315I-inclusive
compound mutants, where 9/10 in our panel showed little or
no sensitivity to ponatinib or any of the other TKIs tested.We pro-
vide examples of clinical ponatinib failure attributable to E255V/
T315I, T315I/F359C, Y253H/T315I, T315I/H396R, and T315I/
E453K. Given the unique efficacy of ponatinib against the
T315I single mutant and its current revised U.S. clinical indica-
tion, a significant fraction of future patients treatedwith ponatinib
will be expected to harbor a T315I mutation at baseline. More
sensitive, routine screening of baseline samples from these
patients may be warranted to determine whether problematic
T315I-inclusive compound mutants are present.
Detection of two mutations by conventional sequencing does
not provide sufficient information to identify the best treatment
option since this may represent two clones, each with a single
mutation. In contrast, cloning and sequencing discerns com-
pound from polyclonal mutations. For example, while patients
#10, #26, and #35 each had two baseline mutations by conven-
tional sequencing, cloning and sequencing demonstrated
mutual exclusivity of these mutations at the clonal level. Verifica-
tion that Y253H and E255V exist in different clones as opposed
to as a highly ponatinib-resistant Y253H/E255V compound
mutant (patient #35) is of importance for clinical decision-
making.
In our study, no patient beginning ponatinib with native BCR-
ABL1 by conventional sequencing exhibited a causative com-
pound mutation at EOT, similar to reports on BCR-ABL1 single
mutants (Khorashad et al., 2008; Soverini et al., 2009). These re-
sults suggest that patients who failed multiple TKIs without a
BCR-ABL1 mutation are unlikely to experience ponatinib failure
due to emergence of a resistance-conferring compound muta-
tion. Effective therapy for these patients may require a synthetic
lethality approach, involving blockade of a second pathway in
addition to BCR-ABL1. Additionally, consistent with inferred
compound mutational status data reported in the PACE trial
(Cortes et al., 2013), we found detection of compoundmutations
at EOT to be more frequent among CML-BP and Ph+ ALL pa-
tients than those with CML-CP, suggesting an increased risk of
compound mutation-based ponatinib resistance in advanced
disease. Although we identified a number of resistance-confer-
ring compound mutants at EOT, longer follow-up and a largerCanumber of specimens will be required to make definitive prog-
nostic use of baseline sequencing profiles of patients beginning
a new TKI.
Among the 12 key positions identified, there appear to be pair-
ing constraints for generation of TKI-resistant compound mu-
tants. For example, the current snapshot of reported compound
mutations includes position 315 in compound with 9/11 other
key positions, whereas position 252 has only been reported in
compound with positions 255 and 315. We also observed that
among the 66 possible pairwise combinations of the 12 key
residues, the spectrum and frequency of pairings reported to
date appear to represent a nonrandom distribution (c2 =
42.39; df = 3; p < 0.0001). While additional resistant pairings
will undoubtedly be observed in the future, findings to date
may suggest that only a limited number of compound mutation
possibilities avoid deleterious, nontolerated effects on kinase
function (Corbin et al., 2002) or fitness of themutated clone (Gris-
wold et al., 2006; Shah et al., 2007; Skaggs et al., 2006) and are
consistent with our observation that the number of missense
mutations tolerated by the kinase appears to be limited.
The broad potency of ponatinib against BCR-ABL1 point mu-
tants can be traced to the extensive network of contacts that sta-
bilize its binding to the kinase domain. However, certain pairings
of mutations, each of which is susceptible to a given TKI in isola-
tion, confer increased resistance when present as a compound
mutation. Molecular dynamics-guided modeling performed for
Y253H/E255V, E255V/T315I, and I315M reveals commonalities
that could aid in designing TKIs to treat compound mutants.
For instance, several compound mutations involving the P loop
result in significant distortion of this region, suggesting it may
prove advantageous to minimize direct TKI/P loop interactions.
Also intriguing is our characterization of an I315M point mutation
in clinical resistance to ponatinib due to direct encroachment of
the mutant side chain on drug binding (patient #22). Notably,
ponatinib is a poor inhibitor of kinases in which methionine is
the native gatekeeper position analogous to BCR-ABL1 position
315. For example, the insulin receptor is500-fold less sensitive
to ponatinib than ABL1T315I (O’Hare et al., 2009). By contrast, the
T315A mutant is uniquely resistant to dasatinib and inhibited by
each of the other five TKIs including ponatinib (Burgess et al.,
2005; Shah et al., 2004). These findings argue that efforts to
develop future BCR-ABL1 TKIs should also consider the capac-
ity to accommodate multiple different specific substitutions at
the gatekeeper position.
Computational methods have been applied to BCR-ABL1 sin-
gle and compound mutants to predict TKI binding, including
ponatinib (Gibbons et al., 2014; Tanneeru and Guruprasad,
2013). The use of different computational methods and the
inherent limitations of modelingmandate experimental validation
of predictions. For example, one computational approach iden-
tified T315I/F359V as 4-fold more resistant to ponatinib than
Y253H/T315I (Gibbons et al., 2014). In contrast, our comprehen-
sive, direct experimental comparison of compound mutants and
findings in cell-based resistance analyses identify Y253H/T315I
as 3.5-fold more ponatinib resistant than T315I/F359V (O’Hare
et al., 2009).
It is impossible to predict exactly how many patients diag-
nosed with CML or Ph+ ALL will develop resistance due to
BCR-ABL1 compound mutations. Fortunately, most CML-CPncer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier Inc. 439
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responses and are at a low risk for acquiring compound muta-
tions. In contrast, TKI failure remains common in CML-BP and
Ph+ ALL, and the incidence of compound mutations may in-
crease with the number of successive TKI therapies (Shah
et al., 2007). Although patients with compound mutations repre-
sent only a minority of Ph+ leukemias, they currently lack a tar-
geted therapy option and their prognosis is poor (Cortes et al.,
2013), highlighting the need to identify therapeutic strategies
that minimize mutational escape in Ph+ leukemia. In addition,
our findings are relevant to other cancers in which compound
mutations are a predicted mechanism of therapy escape,
including acute myeloid leukemia (Smith et al., 2013) and non-
small cell lung cancer (Awad et al., 2013; Davare et al., 2013).
Development of therapeutic strategies to control and target
compound mutation-based resistance in Ph+ leukemia will also
provide a blueprint for similar discovery in other cancers.
EXPERIMENTAL PROCEDURES
Inhibitors
Inhibitors were prepared as 10.0 mM stock solutions in phosphate-buffered
saline (imatinib) or DMSO and stored at 20C. Serial dilutions of stock solu-
tions were carried out before each experiment.
Cellular Proliferation Assays
Ba/F3 BCR-ABL1-expressing cells were plated in 96-well plates (23 103 cells/
well) and incubated in 2-fold escalating concentrations of dasatinib, ponatinib
(0–768 nM), imatinib, nilotinib, rebastinib, or bosutinib (0–10,240 nM) for 72 hr.
Proliferation was assessed by methanethiosulfonate-based viability assay
(CellTiter 96 AQueous One; Promega). IC50 values are reported as the mean
of three independent experiments performed in quadruplicate. See also Sup-
plemental Experimental Procedures.
Isolation of Primary Ph+ Leukemia Cells from Blood or Bone Marrow
All patients were consented in accordance with the Declaration of Helsinki and
the Belmont Report, and University of Utah Institutional Review Board
approved all studies with human specimens. Mononuclear cells (MNCs)
were isolated from primary patient peripheral blood or bone marrow speci-
mens by Ficoll-separation. CD34+ cells were enriched by magnetic column
separation using a CD34 human microbead kit and the POSSELDS program
(AutoMACS; Miltenyi). Purity of the CD34+ fraction was determined to be
>90% by fluorescence-activated cell sorting. If MNC yield was limiting
(<2 3107 cells), the RNA isolation described below was done with an aliquot
of MNCs. See also Supplemental Experimental Procedures.
Conventional and Clonal Sequencing of the BCR-ABL1 Kinase
Domain
RNA obtained from primary Ph+ leukemia cell lysates (QIAGEN RNeasy Mini
Kit) served as template for cDNA synthesis (BioRad iScript cDNA Synthesis
Kit) as recommended by the manufacturer. Amplification of the BCR-ABL1
kinase domain was done by two-step PCR to exclude amplification of normal
ABL1 (Khorashad et al., 2006; Shah et al., 2007). PCR products were electro-
phoresed on a 2% agarose gel to confirm amplification, purified (QIAquick
PCR Purification Kit; QIAGEN), and subjected to (1) conventional Sanger
sequencing in both directions using BigDye terminator chemistry on an
ABI3730 instrument (Khorashad et al., 2006), and (2) cloning and sequencing
of amplified fragments introduced into E. coli TOP10 cells (TOPO cloning sys-
tem; Invitrogen) (Khorashad et al., 2013). For cloning and sequencing, individ-
ual bacterial colonies (average: 85/specimen; range: 23–100), each carrying a
recombinant plasmid with a single BCR-ABL1 kinase domain amplicon in-
serted, were subjected to BCR-ABL1 kinase domain amplification and Sanger
sequenced in both directions (Beckman Coulter Genomics). DNA sequence
analysis was done with Mutation Surveyor software (SoftGenetics) (O’Hare
et al., 2009).440 Cancer Cell 26, 428–442, September 8, 2014 ª2014 Elsevier IncImmunoblot Analysis of BCR-ABL1 Tyrosine Phosphorylation
Ba/F3 cells expressing native or compound mutant BCR-ABL1 were cultured
for 4 hr in standard medium alone or with escalating concentrations of TKI,
followed by boiling for 10min in SDS-PAGE loading buffer. Lysates were sepa-
rated on 4%–15% Tris-glycine gels, transferred, and immunoblotted with
antibodies for the BCR N terminus (3902; Cell Signaling) and phospho-ABL1
(Y393 [1a numbering]; Cell Signaling).
Molecular Dynamics Simulations
Mutant conformations of the ABL1 kinase were prepared using standard
methods to generate ABL1Y253H/E255V, ABL1E255V/T315I, and ABL1I315M. For
each mutant, both the active (Protein Data Bank [PDB] entry 2GQG; Tokarski
et al., 2006) and inactive (PDB entry 2HYY; Manley et al., 2005) conformations
of ABL1 kinase were created. The Nanoscale Molecular Dynamics simulation
package was used for molecular dynamics simulation, and the Amber ff12SB
force field was employed for standard protein parameters. See also Supple-
mental Experimental Procedures.
Docking Simulations
The Schro¨dinger suite of programs (Suite 2012:Maestro, version 9.3) was used
for docking studies. In the final 50 ns of the simulation, 50 conformations were
extracted as docking receptors. Selected conformations were prepared using
Protein Preparation Wizard. Ligands (ponatinib and dasatinib) were prepared
(Suite 2012: LigPrep, version 2.5) and initial docking simulation was performed
using the GlideXP module (version 5.7) of the Schro¨dinger program. To
enhance binding conformations and allow receptor flexibility, docked confor-
mations were subjected to induced fit simulations. Docking scores were
computed using the GlideXP module. See also Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and nine tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.07.006.
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